利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.027 秒)

    Method, system, and program product for automatically formatting electronic mail
    1.
    发明申请
    Method, system, and program product for automatically formatting electronic mail 有权
    用于自动格式化电子邮件的方法，系统和程序产品

    公开(公告)号：US20050027781A1

    公开(公告)日：2005-02-03

    申请号：US10632137

    申请日：2003-08-01

    申请人： James Curry ,  Dinesh Shenoy

    发明人： James Curry ,  Dinesh Shenoy

    IPC分类号： G06F20060101 ,  G06F15/16 ,  G06Q10/00

    CPC分类号： G06Q10/107

    摘要： The concepts discussed herein address a system, method, and computer product by which an e-mail is automatically formatted. An e-mail is sent by an e-mail client and received by a server for processing outbound and inbound e-mail including a SMTP server, POP3/IMAP server, or another server in communication with the SMTP server, POP3/IMAP server, or both. The server receives the e-mail message from the e-mail client and text-parses the received e-mail for identifying an e-mail attribute. Next, the system formats the received e-mail message in accordance with a predetermined format corresponding to the identified e-mail attribute, which is sent to intended recipient(s).

    摘要翻译： 本文讨论的概念解决了自动格式化电子邮件的系统，方法和计算机产品。 电子邮件由电子邮件客户端发送并由服务器接收，用于处理出站和入站电子邮件，包括SMTP服务器，POP3 / IMAP服务器或与SMTP服务器POP3 / IMAP服务器通信的其他服务器， 或两者。 服务器从电子邮件客户端接收电子邮件，并对接收的电子邮件进行文本解析，以识别电子邮件属性。 接下来，系统根据与所识别的电子邮件属性相对应的预定格式来格式化所接收的电子邮件消息，该邮件属性被发送给预定的接收者。

    MULTI-PHASIC PHARMACEUTICAL FORMULATIONS OF POORLY WATER-SOLUBLE DRUGS FOR REDUCED FED/FASTED VARIABILITY AND IMPROVED ORAL BIOAVAILABILITY
    3.
    发明申请
    MULTI-PHASIC PHARMACEUTICAL FORMULATIONS OF POORLY WATER-SOLUBLE DRUGS FOR REDUCED FED/FASTED VARIABILITY AND IMPROVED ORAL BIOAVAILABILITY 审中-公开
    用于减少FED /改善的变异性和改善的口服生物利用度的多种水溶性药物的多相药物制剂

    公开(公告)号：US20100143420A1

    公开(公告)日：2010-06-10

    申请号：US12523445

    申请日：2008-01-22

    申请人： Dinesh Shenoy ,  Robert Lee

    发明人： Dinesh Shenoy ,  Robert Lee

    IPC分类号： A61K38/12 ,  A61P1/08 ,  A61P9/00 ,  A61P25/00 ,  A61P21/02 ,  A61P7/02 ,  A61K31/216 ,  A61K31/436 ,  A61K31/58 ,  A61K31/192 ,  A61K31/496 ,  A61K31/343 ,  A61K31/5377 ,  A61K9/14

    CPC分类号： A61K9/0095 ,  A61K9/107

    摘要： Pharmaceutical formulations are disclosed comprising a multi-phasic pharmaceutical composition comprising an active pharmaceutical ingredient, wherein the active pharmaceutical ingredient is in a particulate state, a solubilized state, or in both a particulate state and in a solubilized state; a solvent; a non-miscible liquid; a stabilizer, and water; wherein the pharmaceutical formulation is an oral dosage form. Such pharmaceutical formulations are capable of reducing the fed/fast variability and improving oral bioavailability to which a number of active pharmaceutical ingredients are susceptible. The pharmaceutical formulations of the invention, therefore are bioequivalent in fed and fasted states and improved oral bioavailability.

    摘要翻译： 公开了药物制剂，其包含含有活性药物成分的多相药物组合物，其中所述活性药物成分处于颗粒状态，溶解状态，或者处于微粒状态和溶解状态; 溶剂; 不混溶液体; 稳定剂和水; 其中所述药物制剂是口服剂型。 这样的药物制剂能够降低进食/快速变异性并改善许多活性药物成分敏感的口服生物利用度。 因此，本发明的药物制剂在进食和禁食状态下是生物等效的，并且改善了口服生物利用度。

    Nanoparticulate delivery systems for treating multi-drug resistance
    8.
    发明申请
    Nanoparticulate delivery systems for treating multi-drug resistance 审中-公开
    用于治疗多药耐药的纳米颗粒递送系统

    公开(公告)号：US20060257493A1

    公开(公告)日：2006-11-16

    申请号：US11413067

    申请日：2006-04-27

    申请人： Mansoor Amiji ,  Dinesh Shenoy ,  Lilian Vlerken

    发明人： Mansoor Amiji ,  Dinesh Shenoy ,  Lilian Vlerken

    IPC分类号： A61K31/739 ,  A61K31/337 ,  A61K31/138 ,  A61K9/14

    CPC分类号： A61K9/5123 ,  A61K9/1075 ,  A61K31/138 ,  A61K31/337 ,  A61K31/739

    摘要： An encapsulated delivery system, and, in particular, a nanoparticulate delivery system representing a qualitatively different approach to overcoming multi-drug resistance while simultaneously administering the chosen drug treatment to a patient, e.g., in a site-specific manner, is disclosed. A composition according to the invention includes a therapeutically effective amount of one or more multi-drug resistance reversing agents selected from the group consisting of ceramide and ceramide modulators; and a therapeutically effective amount of a therapeutic agent, wherein the therapeutic agent is different from the one or more multi-drug resistance reversing agents, and the one or more multi-drug resistance reversing agents and the therapeutic agent are encapsulated, preferably co-encapsulated, in a biocompatible, biodegradable delivery vehicle for delivery to a patient in need of treatment, for example, for specific localization at, or higher probability of delivery to, a treatment site in a patient administered the composition. Preferably, the one or more multi-drug resistance reversing agents are ceramide, paclitaxel or tamoxifen.

    摘要翻译： 公开了一种封装的递送系统，特别是纳米颗粒递送系统，其代表克服多重耐药性的定性不同的方法，同时以例如以特定位点的方式向患者施用所选择的药物治疗。 根据本发明的组合物包括治疗有效量的一种或多种选自神经酰胺和神经酰胺调节剂的多药耐药逆转剂; 和治疗有效量的治疗剂，其中治疗剂不同于一种或多种多药耐药反转剂，并且一种或多种多药耐药逆转剂和治疗剂被包封，优选共包封 在生物相容的，可生物降解的递送载体中，用于递送至需要治疗的患者，例如用于给予组合物的患者的治疗部位的特定定位或更高的可能性。 优选地，一种或多种多药耐药逆转剂是神经酰胺，紫杉醇或他莫昔芬。